600873 梅花生物
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入12,235,095-0.37%24,208,67525,069,28827,760,61227,937,153
减:营业总成本11,604,84511.92%21,603,82121,862,60024,158,62322,990,081
    其中:营业成本10,653,09412.93%19,609,39920,036,69922,297,12220,915,784
               财务费用53,600-359.43%4,005(117,264)(33,427)83,877
               资产减值损失(29,798)222.61%(36,035)(6,982)(5,415)(5,958)
公允价值变动收益21,33733.21%32,83814,826(38,116)32,687
投资收益57,91297.98%57,84830,1937,62724,365
    其中:对联营企业和合营企业的投资收益(2,122)129.87%(2,117)(3,018)1,8463,074
营业利润818,778-60.94%2,909,0623,491,2853,813,3935,160,179
利润总额830,403-60.25%3,729,7003,349,4613,723,1365,152,795
减:所得税费用168,540-47.53%448,820609,033542,186746,553
净利润661,863-62.56%3,280,8802,740,4273,180,9504,406,242
减:非控股权益------------
股东净利润661,863-62.56%3,280,8802,740,4273,180,9504,406,242

市场价值指针
每股收益 (元) *0.240-61.29%1.1700.9401.0601.440
每股派息 (元) *----0.4290.6020.4200.400
每股净资产 (元) *5.5886.42%5.8305.1094.8124.442
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容